tiprankstipranks
Trending News
More News >
Kazia Therapeutics Limited (KZIA)
NASDAQ:KZIA
US Market

Kazia Therapeutics (KZIA) AI Stock Analysis

Compare
298 Followers

Top Page

KZ

Kazia Therapeutics

(NASDAQ:KZIA)

Rating:31Underperform
Price Target:
Kazia Therapeutics has a low overall stock score due to significant financial instability marked by declining revenues, negative equity, and cash flow issues. Technical indicators suggest bearish momentum, and poor valuation metrics reflect the company's unprofitability. The absence of dividends and positive earnings call or corporate events data further emphasize the company's challenges.
Positive Factors
Clinical Trial Progress
The first patient has been dosed in the Phase 1b trial evaluating paxalisib in combination with immunotherapies for triple-negative breast cancer.
Financial Stability
The breast cancer study is funded by investigators and does not require capital investments from Kazia, which is beneficial for the company's financial stability.
Market Opportunity
Paxalisib is being evaluated for treating resistant triple negative breast cancer, which presents a significant market opportunity, and data from this study could be impactful.
Negative Factors
Financial Challenges
The financing market remains difficult due to current market conditions and Kazia’s market cap.
Financing Risk
Phase 3 for glioblastoma multiforme (GBM) has not yet initiated and is financing dependent, which poses a risk for future developments.

Kazia Therapeutics (KZIA) vs. SPDR S&P 500 ETF (SPY)

Kazia Therapeutics Business Overview & Revenue Model

Company DescriptionKazia Therapeutics Limited (KZIA) is an innovative oncology-focused biotechnology company based in Australia. It is dedicated to the development and commercialization of novel therapeutics for the treatment of cancer. The company's lead program is paxalisib, a brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, which is currently in clinical trials for glioblastoma, a highly aggressive form of brain cancer. Kazia Therapeutics aims to address unmet medical needs by advancing its drug candidates through rigorous clinical trials and regulatory processes.
How the Company Makes MoneyKazia Therapeutics primarily generates revenue through the development and potential commercialization of its drug candidates. The company seeks to advance its therapies through clinical trials and, upon successful results and regulatory approval, aims to license its drugs to larger pharmaceutical companies or bring them to market directly. Key revenue streams include milestone payments, royalties from licensing agreements, and potential sales revenue of approved drugs. Partnerships with research institutions and pharmaceutical companies also play a crucial role in funding and advancing their drug development programs.

Kazia Therapeutics Financial Statement Overview

Summary
Kazia Therapeutics is facing financial challenges with declining revenues, persistent losses, and negative equity. The company struggles with cash flow generation and financial stability, which could affect its ability to sustain operations without significant changes or external funding.
Income Statement
20
Very Negative
Kazia Therapeutics has shown declining revenue over the years with a significant drop in total revenue in the most recent period. The company is experiencing a negative net profit margin, indicating it is not profitable. Moreover, both EBIT and EBITDA margins are negative, highlighting operational inefficiencies and challenges in controlling costs.
Balance Sheet
30
Negative
The company's financial structure is concerning, with negative stockholders' equity in the latest period, indicating liabilities exceed assets. The debt-to-equity ratio is not applicable due to negative equity, which poses a financial risk. Moreover, the equity ratio is negative, underscoring the financial instability and leverage issues.
Cash Flow
25
Negative
There is a negative operating cash flow and free cash flow, indicating that the company is not generating sufficient cash from its operations. The free cash flow growth rate is negative, suggesting worsening liquidity and inability to cover expenses without external financing.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue2.31M555.0025.0015.18M1.06K
Gross Profit2.31M555.0025.0015.18M1.06K
EBITDA-26.77M-22.28M-23.51M-5.11M-11.11M
Net Income-26.78M-20.47M-24.65M-8.42M-12.47M
Balance Sheet
Total Assets21.59M28.09M34.96M58.09M23.06M
Cash, Cash Equivalents and Short-Term Investments1.66M5.24M7.36M27.59M8.76M
Total Debt634.00K1.80M1.84M0.000.00
Total Liabilities31.60M16.03M16.32M20.24M8.94M
Stockholders Equity-10.02M12.05M18.64M37.85M14.13M
Cash Flow
Free Cash Flow-9.58M-15.16M-22.76M-9.11M-8.81M
Operating Cash Flow-9.58M-15.16M-22.76M-9.11M-8.81M
Investing Cash Flow0.000.00-2.36M0.000.00
Financing Cash Flow5.99M12.97M3.73M28.11M12.14M

Kazia Therapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price6.82
Price Trends
50DMA
5.23
Positive
100DMA
4.74
Positive
200DMA
11.58
Negative
Market Momentum
MACD
0.32
Positive
RSI
53.72
Neutral
STOCH
49.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KZIA, the sentiment is Positive. The current price of 6.82 is below the 20-day moving average (MA) of 7.38, above the 50-day MA of 5.23, and below the 200-day MA of 11.58, indicating a neutral trend. The MACD of 0.32 indicates Positive momentum. The RSI at 53.72 is Neutral, neither overbought nor oversold. The STOCH value of 49.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KZIA.

Kazia Therapeutics Risk Analysis

Kazia Therapeutics disclosed 37 risk factors in its most recent earnings report. Kazia Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Holders of the ADSs are not treated as holders of our ordinary shares. Q2, 2024
2.
We have a history of operating losses and we expect to continue to incur losses and may never be profitable. Q2, 2024
3.
If the Company fails to comply with the rules under the Sarbanes-Oxley Act of 2002 related to accounting controls and procedures in the future, or, if the Company discovers material weaknesses and other deficiencies in our internal control and accounting procedures, the price of the ADSs could decline significantly and raising capital could be more difficult. Q2, 2024

Kazia Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$7.45B0.27-61.87%2.30%16.62%1.04%
45
Neutral
$578.67K-89.21%-83.72%99.56%
43
Neutral
$5.63M-53.16%-1.56%5.01%
42
Neutral
$14.97M-714.96%978.39%69.65%
31
Underperform
$7.32M-3028.18%19.58%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
KZIA
Kazia Therapeutics
6.82
-26.59
-79.59%
BDRX
Biodexa Pharmaceuticals
0.87
-16.91
-95.11%
SONN
Sonnet BioTherapeutics Holdings
4.47
-2.25
-33.48%
XBIO
Xenetic Biosciences
3.93
0.00
0.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 21, 2025